Adjuvant Osimertinib and Advanced EGFR-Mutated NSCLC | NEJM

Описание к видео Adjuvant Osimertinib and Advanced EGFR-Mutated NSCLC | NEJM

Patients with unresectable stage III EGFR-mutated non–small-cell lung cancer have no approved targeted treatments available.

Research findings on adjuvant osimertinib are summarized in a new Quick Take video.

To see the full article, follow this link: https://nej.md/451OXwi

#oncology #pulmonology #criticalcare #clinicaltrials #nejm

Комментарии

Информация по комментариям в разработке